New drug combo may let some cancer patients skip harsh chemo
NCT ID NCT07177443
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This study tests whether adding the drug serplulimab to standard induction chemotherapy can allow patients with advanced nasopharyngeal cancer to safely skip the intense concurrent chemotherapy that usually follows. The trial will enroll 456 adults aged 18-65 with previously untreated, locally advanced disease. The goal is to see if this approach improves survival and reduces side effects like vomiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.